Cargando…

IMMU-23. RESEARCH ON MULTI-ANTIGEN T CELL INFUSION AGAINST NEURO-ONCOLOGIC DISEASE (ReMIND)

INTRODUCTION: Pediatric patients with recurrent or progressive central nervous system (CNS) tumors have poor prognoses and clearly require improved therapies. Previous studies that used ex vivo expanded T cells show promising efficacy against viral infections. The polyclonal nature of these T cells,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cruz, Conrad Russell, Gomez, Stephanie, Geiger, Ashley, Grant, Melanie, DiCioccio, Rachel, Fortiz, Maria, Lang, Haili, Datar, Anushree, Shibli, Abeer, Reynolds, Emily, Lazarski, Christopher, Wachspress, Mariah, Pezzella, Gloria, Gomez, Daisy, Tanna, Jay, Hoq, Fahmida, Hanley, Patrick, Kilburn, Lindsay, Rood, Brian, Packer, Roger, Bollard, Catherine, Hwang, Eugene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Immunology/Immunotherapy - IMMU
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260129/ http://dx.doi.org/10.1093/neuonc/noad073.210

Ejemplares similares

EPCT-15. THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS
por: Grant, Melanie, et al.
Publicado: (2020)

EPCT-24 THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS
por: Grant, Melanie, et al.
Publicado: (2021)

IMMU-22. ALLOGENEIC NK CELLS SECRETING IL15 AND RESISTANT TO TGF-β Show Antitumor Activity Against Gliobastoma
por: Muniraj, Nethaji, et al.
Publicado: (2023)

IMMU-12. T CELL SEQUESTRATION IN POSTERIOR FOSSA TUMORS
por: Wilson, Zach, et al.
Publicado: (2023)

IMMU-06. SYSTEMIC MRNA VACCINES RESET IMMUNOGENICITY AGAINST DIFFUSE MIDLINE GLIOMA
por: McGuiness, James, et al.
Publicado: (2023)

IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH
por: Kampers, Linde F C, et al.
Publicado: (2023)

IMMU-20. EVALUATION OF B7-H3 NANOBODY CAR-T CELLS IN PEDIATRIC GLIOBLASTOMA
por: Fanuzzi, Mia, et al.
Publicado: (2023)

IMMU-16. IDENTIFICATION OF TUMOR REJECTION ANTIGENS FOR PRECISION ADOPTIVE CELLULAR THERAPY FOR PEDIATRIC GLIOMAS
por: Trivedi, Vrunda, et al.
Publicado: (2023)

IMMU-11. PRECLINICAL HIGH-RISK PEDIATRIC BRAIN TUMOR MODELS FOR IMMUNOTHERAPY: HURDLES AND THE WAY FORWARD
por: Mishra, Deepak, et al.
Publicado: (2023)

IMMU-17. DEVELOPMENT OF AN INTRACRANIAL CANNULA IMPLANTATION SYSTEM FOR SERIAL LOCOREGIONAL CAR T CELL INFUSIONS IN MICE
por: Harvey, Kyra, et al.
Publicado: (2023)

IMMU-18. TARGETING GD2 IN THALAMIC DIFFUSE MIDLINE GLIOMA WITH TRANSIENT MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2023)

IMMU-19. NIVOLUMAB-INDUCED CNS DEMYELINATION IN A 15-YEAR-OLD WITH CLASSIC HODGKIN LYMPHOMA
por: Ramirez, Alejandra, et al.
Publicado: (2023)

IMMU-21. ELUCIDATING THE CELLULAR MECHANISMS OF THERAPEUTIC BENEFIT UNDERLYING ADOPTIVE CELLULAR THERAPY IN MODELS OF GLIOMA
por: Figg, John, et al.
Publicado: (2023)

IMMU-10. PILOCYTIC ASTROCYTOMAS SHOW EVIDENCE OF INTRINSIC IMMUNE SURVEILLANCE AND ACTIVATION WITHIN THE TUMOR MICROENVIRONMENT
por: Najem, Hinda, et al.
Publicado: (2023)

IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS
por: Hoare, Owen, et al.
Publicado: (2023)

IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY
por: Thompson, Eric, et al.
Publicado: (2023)

IMMU-01. EVALUATING THE IMPACT OF CAR DESIGN ON THE TUMOR IMMUNE MICROENVIRONMENT AND ANTI-TUMOR RESPONSE IN SYNGENEIC GLIOMA MODELS
por: Haydar, Dalia, et al.
Publicado: (2023)

IMMU-05. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
por: Mahdi, Jasia, et al.
Publicado: (2023)

IMMU-14. WAKING THE SLEEPING GIANT: TLR7/8 AGONIST TREATMENT STIMULATES TUMOR-ASSOCIATED MYELOID CELLS FOR MEDULLOBLASTOMA IMMUNOTHERAPY
por: Pauneto, Coral Alicea, et al.
Publicado: (2023)

IMMU-08. SALVAGE IMMUNOTHERAPIES FOR REPLICATION REPAIR DEFICIENT (RRD) HIGH-GRADE GLIOMA FAILING ANTI-PD1 MONOTHERAPY: AN IRRDC REPORT
por: Das, Anirban, et al.
Publicado: (2023)

IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
por: Owens, Geoffrey, et al.
Publicado: (2023)

IMMU-15. PHASE I TRIAL OF GD2.CART-CELLS AUGMENTED WITH A CONSTITUTIVELY ACTIVE INTERLEUKIN-7 RECEPTOR (C7R) FOR TREATMENT OF HIGH-GRADE PEDIATRIC CNS TUMORS
por: Lin, Frank, et al.
Publicado: (2023)

IMMU-13. PRECLINICAL EFFICACY OF MULTI-ANTIGEN (HER2/EGFR806/B7-H3/IL13RA2) TARGETING QUAD-CAR T CELLS AGAINST DIFFUSE MIDLINE GLIOMA
por: Myers, Carrie, et al.
Publicado: (2023)

IMMU-07. TACEDINALINE (CI994), A CLASS I HDAC INHIBITOR, TARGETS INTRINSIC TUMOR GROWTH AND LEPTOMENINGEAL DISSEMINATION IN MYC-DRIVEN MEDULLOBLASTOMA WHILE MAKING THEM SUSCEPTIBLE TO ANTI-CD47 INDUCED MACROPHAGE PHAGOCYTOSIS VIA NF-KB-TGM2 DRIVEN TUMOR INFLAMMATION
por: Marquardt, Viktoria, et al.
Publicado: (2023)

T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1
por: Harris, Katherine M., et al.
Publicado: (2020)

Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease
por: Kinoshita, Hannah, et al.
Publicado: (2022)

Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT
por: Kinoshita, Hannah, et al.
Publicado: (2022)

IMMU-15. PROTEOGENOMIC DISCOVERY OF NOVEL TUMOR PEPTIDES AS NEOANTIGENS FOR PERSONALIZED T CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA
por: Rivero-Hinojosa, Samuel, et al.
Publicado: (2020)

Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains
por: Stanojevic, Maja, et al.
Publicado: (2022)

Coronavirus-Specific T-Cells Can be Rapidly Expanded from Convalescent Donors for Potential Clinical Use
por: Keller, Michael D., et al.
Publicado: (2021)

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein
por: Keller, Michael D., et al.
Publicado: (2020)

Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma
por: Dave, Hema, et al.
Publicado: (2022)

Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products
por: Durkee-Shock, Jessica, et al.
Publicado: (2022)

Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency
por: Kinoshita, Hannah, et al.
Publicado: (2021)

IMMU-13. CUSTOMIZABLE MULTI-LAMELLAR RNA-NANOPARTICLES FOR PEDIATRIC GLIOMA
por: Mendez-Gomez, Hector, et al.
Publicado: (2021)

IMMUNOPOTENTIATION BY IMMU 21 IN IMMUNOCOMPROMISED RATS
por: Chatterjee, S., et al.
Publicado: (1997)

EPEN-09. UTILITY OF RADIATION THERAPY IN SPINAL CORD MYXOPAPILLARY EPENDYMOMAS: A REVIEW OF THE LITERATURE
por: Jackson, Kasey, et al.
Publicado: (2023)

MDB-17. THE PTBP2 SPLICING FACTOR IS ESSENTIAL IN GROUP 3/4 MEDULLOBLASTOMA
por: Caisova, Veronika, et al.
Publicado: (2023)

IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020)

SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection
por: Conway, Susan R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7gnam1aqvudb8rdkcu6ae1o686